Literature DB >> 25526087

Loss of JUNB/AP-1 promotes invasive prostate cancer.

M K Thomsen1, L Bakiri1, S C Hasenfuss1, H Wu1, M Morente2, E F Wagner1.   

Abstract

Prostate cancer is a frequent cause of male death in the Western world. Relatively few genetic alterations have been identified, likely owing to disease heterogeneity. Here, we show that the transcription factor JUNB/AP-1 limits prostate cancer progression. JUNB expression is increased in low-grade prostate cancer compared with normal human prostate, but downregulated in high-grade samples and further decreased in all metastatic samples. To model the hypothesis that this downregulation is functionally significant, we genetically inactivated Junb in the prostate epithelium of mice. When combined with Pten (phosphatase and tensin homologue) loss, double-mutant mice were prone to invasive cancer development. Importantly, invasive tumours also developed when Junb and Pten were inactivated in a small cell population of the adult anterior prostate by topical Cre recombinase delivery. The resulting tumours displayed strong histological similarity with human prostate cancer. Loss of JunB expression led to increased proliferation and decreased senescence, likely owing to decreased p16(Ink4a) and p21(CIP1) in epithelial cells. Furthermore, the tumour stroma was altered with increased osteopontin and S100 calcium-binding protein A8/9 expression, which correlated with poor prognoses in patients. These data demonstrate that JUNB/AP-1 cooperates with PTEN signalling as barriers to invasive prostate cancer, whose concomitant genetic or epigenetic suppression induce malignant progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25526087      PMCID: PMC4356344          DOI: 10.1038/cdd.2014.213

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  40 in total

1.  c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.

Authors:  S-Y Chen; C Cai; C J Fisher; Z Zheng; J Omwancha; C-L Hsieh; L Shemshedini
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

2.  Induction of transcriptionally active Jun proteins regulates drug-induced senescence.

Authors:  Orli Yogev; Shira Anzi; Kazushi Inoue; Eitan Shaulian
Journal:  J Biol Chem       Date:  2006-09-11       Impact factor: 5.157

3.  Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver.

Authors:  Axel Behrens; Maria Sibilia; Jean-Pierre David; Uta Möhle-Steinlein; François Tronche; Günther Schütz; Erwin F Wagner
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

4.  JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Authors:  Anette Hübner; David J Mulholland; Claire L Standen; Maria Karasarides; Julie Cavanagh-Kyros; Tamera Barrett; Hongbo Chi; Dale L Greiner; Cathy Tournier; Charles L Sawyers; Richard A Flavell; Hong Wu; Roger J Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

5.  Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Authors:  Jeffrey C Francis; Afshan McCarthy; Martin K Thomsen; Alan Ashworth; Amanda Swain
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

6.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Authors:  Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-07       Impact factor: 11.205

7.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

8.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

9.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Authors:  A H M Reid; G Attard; L Ambroisine; G Fisher; G Kovacs; D Brewer; J Clark; P Flohr; S Edwards; D M Berney; C S Foster; A Fletcher; W L Gerald; H Møller; V E Reuter; P T Scardino; J Cuzick; J S de Bono; C S Cooper
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

10.  Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects.

Authors:  Lukas Kenner; Astrid Hoebertz; F Timo Beil; Timo Beil; Niamh Keon; Florian Karreth; Robert Eferl; Harald Scheuch; Agnieszka Szremska; Michael Amling; Marina Schorpp-Kistner; Peter Angel; Erwin F Wagner
Journal:  J Cell Biol       Date:  2004-02-09       Impact factor: 10.539

View more
  10 in total

Review 1.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

2.  Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration.

Authors:  Maria Riedel; Martin F Berthelsen; Latifa Bakiri; Erwin F Wagner; Martin K Thomsen
Journal:  J Vis Exp       Date:  2018-04-27       Impact factor: 1.355

3.  MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.

Authors:  Mehdi Sadeghi; Bijan Ranjbar; Mohamad Reza Ganjalikhany; Faiz M Khan; Ulf Schmitz; Olaf Wolkenhauer; Shailendra K Gupta
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

4.  Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer.

Authors:  Janet P C Wong; Ran Wei; Peng Lyu; Olivia L H Tong; Shu Dong Zhang; Qing Wen; Hiu Fung Yuen; Mohamed El-Tanani; Hang Fai Kwok
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

5.  Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.

Authors:  Hannah Nip; Altaf A Dar; Sharanjot Saini; Melissa Colden; Shahryari Varahram; Harshika Chowdhary; Soichiro Yamamura; Yozo Mitsui; Yuichiro Tanaka; Taku Kato; Yutaka Hashimoto; Marisa Shiina; Priyanka Kulkarni; Pritha Dasgupta; Mitsuho Imai-Sumida; Z Laura Tabatabai; Kirsten Greene; Guoren Deng; Rajvir Dahiya; Shahana Majid
Journal:  Oncotarget       Date:  2016-10-18

6.  Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway.

Authors:  Junlin Shi; Lihui Wang; Chunlin Zou; Yudui Xia; Siyuan Qin; Evan Keller; Atsushi Mizokami; Jian Zhang; Yi Lu
Journal:  Oncotarget       Date:  2018-01-09

Review 7.  COX-2 as a potential biomarker and therapeutic target in melanoma.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Mihai Lupu; Teodor Kacso; Eniko Kutasi; Andreea Hopârtean; Roland Stretea; Adriana Gabriela Filip
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

Review 8.  Selective antagonism of cJun for cancer therapy.

Authors:  Andrew Brennan; James T Leech; Neil M Kad; Jody M Mason
Journal:  J Exp Clin Cancer Res       Date:  2020-09-11

9.  Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration.

Authors:  Xingbo Long; Huimin Hou; Xuan Wang; Shengjie Liu; Tongxiang Diao; Shicong Lai; Maolin Hu; Shengqi Zhang; Ming Liu; Hong Zhang
Journal:  Cell Death Dis       Date:  2020-09-19       Impact factor: 8.469

10.  JUNB suppresses distant metastasis by influencing the initial metastatic stage.

Authors:  Juliane Wutschka; Bettina Kast; Melanie Sator-Schmitt; Sila Appak-Baskoy; Jochen Hess; Hans-Peter Sinn; Peter Angel; Marina Schorpp-Kistner
Journal:  Clin Exp Metastasis       Date:  2021-07-19       Impact factor: 5.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.